A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

NCT04438304 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: 64Cu-SARTATE

Sponsor

Clarity Pharmaceuticals Ltd